阴道毛滴虫病的诊断与管理:2021年美国疾病控制与预防中心性传播感染治疗指南证据综述
2021年美国疾病控制与预防中心指南证据综述指出,新诊断方法(如即时检验和核酸检测)可提高检测准确性,女性治疗后3个月应重新筛查,多剂量甲硝唑500 mg每日两次连用7天在女性中清除感染优于单次2 g剂量,但男性仍首选单次2 g口服甲硝唑方案。
要点
- 女性滴虫病治疗后3个月建议重新筛查,因重复和持续感染常见。
- 女性多剂量甲硝唑500 mg每日两次连用7天在1个月治愈检测中优于单次2 g剂量。
- 男性首选单次2 g口服甲硝唑方案治疗。
核心结论
- 阴道毛滴虫病是常见的非病毒性性传播感染,新诊断方法可改善检测,女性治疗后3个月重新筛查,女性多剂量甲硝唑方案优于单次剂量,男性仍首选单次2 g口服甲硝唑。
研究设计与样本
- 2021年美国疾病控制与预防中心性传播感染治疗指南的证据综述,总结了阴道毛滴虫病诊断和管理的相关证据。
主要发现
- 女性感染后果包括增加HIV获得风险、宫颈癌、早产和其他不良妊娠结局。
- 女性重复和持续感染常见,建议治疗后3个月重新筛查。
- 阴道毛滴虫对5-硝基咪唑类体外耐药率为4.3%。
- 在HIV阴性女性中,多剂量甲硝唑500 mg每日两次连用7天与单次2 g剂量相比,在1个月治愈检测时减少感染女性比例。
关键数值与推荐
- 女性治疗后3个月重新筛查(推荐)。
- 女性多剂量甲硝唑500 mg每日两次连用7天(优于单次2 g剂量)。
- 男性首选单次2 g口服甲硝唑方案(推荐)。
- 对5-硝基咪唑类耐药率低(4.3%),应监测。
临床怎么用
- 女性滴虫病患者治疗后3个月应重新筛查。
- 女性治疗可选用多剂量甲硝唑500 mg每日两次连用7天。
- 男性治疗首选单次2 g口服甲硝唑。
- 性伴侣应接受 expedited partner treatment(加速伴侣治疗)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trichomonas vaginalis is likely the most prevalent nonviral sexually transmitted infection, affecting an estimated 3.7 million women and men in the United States. Health disparities are prominent in the epidemiology of trichomoniasis, as African Americans are >4 times more likely to be infected than persons of other races. Since publication of the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines, additional data have bolstered the importance of T. vaginalis infection sequelae in women, including increased risk of human immunodeficiency virus (HIV) acquisition, cervical cancer, preterm birth, and other adverse pregnancy outcomes. Less is known about the clinical significance of infection in men. Newly available diagnostic methods, including point-of-care assays and multiple nucleic acid amplification tests, can be performed on a variety of genital specimens in women and men, including urine, allowing more accurate and convenient testing and screening of those at risk for infection. Repeat and persistent infections are common in women; thus, rescreening at 3 months after treatment is recommended. In vitro antibiotic resistance to 5-nitroimidazole in T. vaginalis remains low (4.3%) but should be monitored. High rates of T. vaginalis among sexual partners of infected persons suggest a role for expedited partner treatment. A randomized controlled trial in HIV-uninfected women demonstrated that multidose metronidazole 500 mg twice daily for 7 days reduced the proportion of women with Trichomonas infection at 1 month test of cure compared with women receiving single-dose therapy (2 g). The 2-g single-dose oral metronidazole regimen remains the preferred treatment in men.
引用
- Kissinger PJ, Gaydos CA, Seña AC, et al. Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis. 2022. PMID: 35416973. doi:10.1093/cid/ciac030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。